Literature DB >> 19410117

Cost-effective airway cultures in the cystic fibrosis patient.

Mark D Ghegan1, Sarah K Wise, David R White, Patrick A Flume, C Michael Bowman, Isabel Virella-Lowell, Rodney J Schlosser.   

Abstract

BACKGROUND: Cystic fibrosis (CF) patients have a high incidence of multidrug-resistant infections, rendering CF patients a treatment challenge.
OBJECTIVE: To evaluate culture protocols for CF patients and develop a cost-effective culture regimen that identifies clinically relevant pathogens. STUDY
DESIGN: Retrospective review.
METHODS: At the time of endoscopic sinus surgery, CF patients underwent both sinus and bronchial lavage cultures. Medical records from 2002 to 2006 were reviewed.
RESULTS: Twenty-four cases were identified; 12 had complete sets of cultures. Seven of 12 had sinus aerobic bacteria that were also present in bronchial culture. Anaerobic cultures from both sites were all negative (42%) or nondiagnostic (58%). Thirty-three percent of sinus fungal cultures and 91.6% of bronchial fungal cultures were positive. Sinus acid fast bacillus cultures were all negative.
CONCLUSION: CF culture protocols may be streamlined by eliminating all anaerobic cultures, as well as sinus acid fast bacillus and fungal cultures for a 52% reduction in cost.

Entities:  

Mesh:

Year:  2008        PMID: 19410117     DOI: 10.1016/j.amjoto.2008.03.006

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  2 in total

Review 1.  Sinus bacteriology in patients with cystic fibrosis or primary ciliary dyskinesia: A systematic review.

Authors:  Maria E Møller; Mikkel C Alanin; Christian Grønhøj; Kasper Aanæs; Niels Høiby; Christian von Buchwald
Journal:  Am J Rhinol Allergy       Date:  2017-09-01       Impact factor: 2.467

Review 2.  Molecular detection of CF lung pathogens: current status and future potential.

Authors:  Sally H Pattison; Geraint B Rogers; Martin Crockard; J Stuart Elborn; Michael M Tunney
Journal:  J Cyst Fibros       Date:  2013-02-10       Impact factor: 5.482

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.